Alnylam’s heart drug troubles take center stage at a cardiology conference
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Alnylam’s heart drug troubles take center stage at a cardiology conference" is generating significant coverage in the Business category, with 5 articles from 4 distinct sources tracked by PULSE so far.
Outlets currently covering the story include DirectorsTalk Interviews, Yahoo Finance, Endpoints News and STAT. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 1h ago.
Quick answers
Why is "Alnylam’s heart drug troubles take center stage at a cardiology conference" trending?
Because 4 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (7)
- Alnylam drops as AstraZeneca posts full trial results for failed heart drug Seeking Alpha · 1d ago
- AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching STAT · 1d ago
- Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with 56.72% Potential Upside DirectorsTalk Interviews · 1d ago
- Is Alnylam (ALNY) Turning Expanded HELIOS-B and Zilebesiran Data Into Durable Cardiovascular Leadership? Yahoo Finance · 1d ago
- Future of AstraZeneca’s gene silencer in heart disease uncertain after trial failure Endpoints News · 1d ago
- In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs STAT · 1d ago
- Alnylam’s heart drug troubles take center stage at a cardiology conference STAT · 1d ago